CITATION REPORT List of articles citing

Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials

DOI: 10.1111/ane.13351 Acta Neurologica Scandinavica, 2021, 143, 154-163.

Source: https://exaly.com/paper-pdf/78028262/citation-report.pdf

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
12	Cannabinoids in the Treatment of Epilepsy: A Review. <i>European Medical Journal (Chelmsford, England)</i> ,	7.5	
11	Short-term and long-term efficacy and safety of antiseizure medications in Lennox Gastaut syndrome: A network meta-analysis <i>Seizure: the Journal of the British Epilepsy Association</i> , 2022 ,	3.2	1
10	Anticonvulsant Agents: Cannabidiol and Fenfluramine. 2022, 1-15		O
9	Cannabidiol and epilepsy in Brazil: a current review. 2022 , 80, 182-192		
8	Safety and efficacy of cannabidiol-cannabidiolic acid rich hemp extract in the treatment of refractory epileptic seizures in dogs. 9,		1
7	Cannabis-based magistral formulation is highly effective as an adjuvant treatment in drug-resistant focal epilepsy in adult patients: an open-label prospective cohort study.		O
6	Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. 2022 , 114238		2
5	Therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies. 2022 , 114237		1
4	Anti-convulsant Agents: Cannabidiol and Fenfluramine. 2022 , 3781-3795		О
3	Real-world data on cannabidiol treatment of various epilepsy subtypes: A retrospective, multicenter study.		0
2	The cenobamate-clobazam interaction- evidence of synergy in addition to pharmacokinetic interaction. 2023 , 142, 109156		O
1	Real-world, long-term evaluation of the tolerability and therapy retention of Epidiolex (cannabidiol) in patients with refractory epilepsy. 2023 , 141, 109159		0